Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1825 1
1844 1
1848 1
1849 1
1855 3
1866 2
1869 2
1873 5
1876 1
1892 1
1893 2
1895 2
1897 1
1898 3
1899 1
1900 2
1903 2
1904 1
1905 4
1907 1
1908 1
1909 2
1910 1
1911 2
1912 2
1913 3
1914 1
1915 1
1916 1
1917 2
1918 5
1919 4
1920 3
1921 2
1922 3
1924 3
1925 5
1926 4
1927 2
1928 2
1930 4
1931 2
1932 2
1934 1
1936 1
1938 1
1939 1
1941 1
1942 1
1944 1
1945 8
1946 34
1947 13
1948 113
1949 76
1950 106
1951 99
1952 114
1953 103
1954 136
1955 118
1956 112
1957 119
1958 124
1959 82
1960 4
1961 7
1962 6
1963 112
1964 184
1965 153
1966 103
1967 156
1968 132
1969 152
1970 130
1971 128
1972 167
1973 150
1974 149
1975 360
1976 429
1977 385
1978 448
1979 585
1980 629
1981 740
1982 853
1983 1050
1984 1148
1985 1145
1986 1182
1987 1280
1988 1313
1989 1623
1990 1626
1991 1690
1992 1798
1993 2063
1994 2154
1995 2229
1996 2394
1997 2525
1998 2684
1999 2796
2000 3239
2001 3273
2002 3605
2003 3944
2004 4354
2005 4838
2006 5335
2007 5913
2008 6599
2009 7039
2010 7920
2011 9278
2012 10257
2013 11971
2014 13072
2015 14054
2016 15044
2017 16337
2018 17389
2019 18860
2020 22059
2021 25604
2022 26046
2023 25118
2024 25858
2025 1328

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305,528 results

Results by year

Filters applied: . Clear all
Page 1
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. Guo R, et al. Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. doi: 10.1038/s41571-020-0377-z. Epub 2020 Jun 8. Nat Rev Clin Oncol. 2020. PMID: 32514147 Free PMC article. Review.
Attempts to develop MET-targeted therapies have historically focused on MET-expressing cancers, with limited success. Thus, MET expression in the absence of a genomic marker of MET dependence is a poor predictor of benefit from MET-targeted ther …
Attempts to develop MET-targeted therapies have historically focused on MET-expressing cancers, with limited success. Thus, …
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.
Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB. Wang J, et al. Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573171
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of patients …
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted …
MET Oncogene Targeting for Cancer Immunotherapy.
Lombardi AM, Sangiolo D, Vigna E. Lombardi AM, et al. Int J Mol Sci. 2024 Jun 1;25(11):6109. doi: 10.3390/ijms25116109. Int J Mol Sci. 2024. PMID: 38892318 Free PMC article. Review.
MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era of cancer-targeted therapy. Different approaches have been developed to hamper MET signaling and/or reduce MET (over)expressio …
MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era …
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. Awad MM, et al. J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4. J Clin Oncol. 2016. PMID: 26729443
Among patients with MET exon 14 mutations, 68% were women, and 36% were never-smokers. Stage IV MET exon 14-mutated NSCLCs were significantly more likely to have concurrent MET genomic amplification (mean ratio of MET to chromosome 7, 4.3) and strong c …
Among patients with MET exon 14 mutations, 68% were women, and 36% were never-smokers. Stage IV MET exon 14-mutated NSCLCs wer …
c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD, Shanmugam MK, Gowda SGS, Chinnathambi A, Rangappa KS, Sethi G. Mohan CD, et al. Phytomedicine. 2024 Jun;128:155379. doi: 10.1016/j.phymed.2024.155379. Epub 2024 Jan 18. Phytomedicine. 2024. PMID: 38503157 Review.
The c-MET pathway is deregulated in a broad range of malignancies, due to overexpression of ligands or receptors, genomic amplification, and MET mutations. ...Some of the keywords used for extracting relevant literature are c-MET, natural compound inhibitors …
The c-MET pathway is deregulated in a broad range of malignancies, due to overexpression of ligands or receptors, genomic amplificati …
MET alterations in advanced non-small cell lung cancer.
Sakamoto M, Patil T. Sakamoto M, et al. Lung Cancer. 2023 Apr;178:254-268. doi: 10.1016/j.lungcan.2023.02.018. Epub 2023 Mar 1. Lung Cancer. 2023. PMID: 36924573 Review.
Activation of the MET pathway can occur through several mechanisms, which can complicate the diagnostic and treatment approach. Recently, several MET-directed therapies have been developed with promising results. In this narrative review, we summarize the biology an …
Activation of the MET pathway can occur through several mechanisms, which can complicate the diagnostic and treatment approach. Recen …
Recording and classifying MET receptor mutations in cancers.
Guérin C, Tulasne D. Guérin C, et al. Elife. 2024 Apr 23;13:e92762. doi: 10.7554/eLife.92762. Elife. 2024. PMID: 38652103 Free PMC article. Review.
Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. ...The first MET mutation was discovered in 1997, in hereditary papillary renal cancer …
Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC …
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Corti C, Uliano J, Passaro A, de Marinis F. Spitaleri G, et al. Cancers (Basel). 2023 Sep 28;15(19):4779. doi: 10.3390/cancers15194779. Cancers (Basel). 2023. PMID: 37835473 Free PMC article. Review.
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. ...This review focuses on the prognostic role of MET, the summa …
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET …
Advances in MET tyrosine kinase inhibitors in gastric cancer.
Zhang Y, Shen L, Peng Z. Zhang Y, et al. Cancer Biol Med. 2024 May 10;21(6):484-98. doi: 10.20892/j.issn.2095-3941.2024.0044. Cancer Biol Med. 2024. PMID: 38727001 Free PMC article. Review.
As such, MET-targeting therapies are being actively developed and promising progress has been demonstrated, especially with MET tyrosine kinase inhibitors. ...Building on current knowledge, this review further discusses existing challenges in MET alterations …
As such, MET-targeting therapies are being actively developed and promising progress has been demonstrated, especially with MET …
MET fusions are targetable genomic variants in the treatment of advanced malignancies.
Sun D, Xing X, Wang Y, Hou H. Sun D, et al. Cell Commun Signal. 2024 Jan 9;22(1):20. doi: 10.1186/s12964-023-01454-0. Cell Commun Signal. 2024. PMID: 38195556 Free PMC article. Review.
Therefore, it is believed that MET fusions could be targetable genomic variants of MET, and inhibition of MET is considered an optionable therapeutic choice for patients harboring MET fusions. According to the summary presented in this review, we recom …
Therefore, it is believed that MET fusions could be targetable genomic variants of MET, and inhibition of MET is consid …
305,528 results
You have reached the last available page of results. Please see the User Guide for more information.